New valve for severe tricuspid leak in high-risk patients
Part of Heart & circulation clinical trials.
This trial tests a new device called the Lux-Valve Plus to replace the tricuspid valve without open-heart surgery. It may help people who have severe leaking of the tricuspid valve and are too high-risk for surgery or not eligible for other non-surgical treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 90 years old.
- You have severe tricuspid valve leaking that causes symptoms like shortness of breath or swelling (NYHA stage III or IV).
- Standard medicines have not controlled your symptoms well enough.
- A team of heart doctors has decided you are at high risk for open-heart surgery on the tricuspid valve.
- Your tricuspid valve cannot be treated with the TriClip device available in Hong Kong.
- You are able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This trial tests a new device called Laplace TTVR to replace a leaky tricuspid valve in the heart without open surgery. It is for people with severe symptoms despite medical treatment.
This trial tests a catheter-based procedure (done through the blood vessels) to repair a severely leaky tricuspid valve. It may help people with symptoms or past hospitalizations from tricuspid valve leakage who are higher-risk for standard surgery.
This study tests a new, less invasive way to replace the tricuspid valve (the valve between the right upper and lower heart chambers) in people with severe leakage. The valve is delivered through a vein in the neck or leg, avoiding open-heart surgery.
This trial tests how well a new catheter-based valve system works for people with severe (or worse) tricuspid valve leaking who still have symptoms despite medicines. It aims to improve outcomes by treating the leaking valve without open-heart surgery, if your heart structure and overall health fit the study.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
Hear when a new Tricuspid Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.